Axcellant Establishes Advisory Board to Strengthen Clinical and Strategic Leadership

1. kwi 11, 2026

Axcellant is pleased to announce the formation of its Advisory Board – a group of distinguished experts in clinical science, medical imaging, artificial intelligence and life sciences leadership. The Advisory Board has been established to support the company’s next phase of growth, bringing together complementary perspectives across clinical development, imaging innovation and business strategy.

The Advisory Board Members:

Prof. Juhani Knuuti brings decades of experience at the intersection of nuclear medicine and clinical practice. As an Advisory Board Member, Professor Knuuti supports Axcellant in strategic clinical development and the conception of new clinical programs. His rare combination of nuclear medicine expertise and hands-on clinical routine makes him uniquely positioned to bridge imaging science and real-world patient care. Professor Knuuti also leads the Imaging Corelab activities at Axcellant, providing oversight of the medical aspects of the company’s projects.

Prof. Piotr J. Słomka is a recognised authority in quantitative image analysis and artificial intelligence applied to nuclear cardiology. He advises Axcellant on the strategic design and optimisation of imaging-based clinical studies, with a particular focus on developing automated, reproducible imaging endpoints suitable for multicentre and regulatory-grade trials. His work ensures that Axcellant’s imaging methodologies meet the highest standards of scientific rigour and regulatory acceptance.

Rainer Metzger, Ph.D. contributes deep expertise in business strategy, investor relations and organisational development. With extensive international leadership experience across life sciences and healthcare, he advises on aligning scientific innovation with commercial objectives, building strategic partnerships and scaling the organisation. His track record in business transformation, M&A and go-to-market execution strengthens Axcellant’s ability to translate clinical excellence into sustainable business growth.

Why an Advisory Board matters now

As Axcellant expands its portfolio of clinical imaging services and enters a critical growth phase, the Advisory Board ensures that every strategic decision benefits from world-class scientific and commercial insight. The Board provides independent guidance on clinical programme design, regulatory strategy, technology validation and corporate development – reinforcing the company’s commitment to scientific rigour and operational excellence.

The formation of the Advisory Board reflects Axcellant’s ambition to set new standards in clinical imaging and trial services – backed by the expertise to deliver on that promise.